Hybrid Analogues of Gramicidin S and Gratisin

MAKOTO TAMAKI

Department of Chemistry, Faculty of Science, Toho University,
2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan

(Received for publication February 16, 2004)

Gramicidin S (GS), cyclo(-Val-Orn-Leu-D-Phe-Pro-)₂^{1,2)}, and Gratisin (GR), cyclo(-Val-Orn-Leu-D-Phe-Pro-D-Tyr-)₂^{3~9)},[†] are potent cyclopeptide antibiotics and adopt an antiparallel β -sheet conformation^{10~12)} (Fig. 1). In the studies of the structure-activity relationship of these antibiotics, the mode of action has been proposed that when these antibiotics interact with a cell membrane of target microorganisms, they adopt antiparallel β -sheet conformations with C₂ symmetry and results in disruption of its cell membrane.^{1~9,13)} In addition, no resistance has been found for the antibiotics, because it requires significant alteration of the lipid composition of the cell membrane.¹⁴⁾ In view of the fact that widespread antibiotic resistance has become a serious threat to public health^{15~18)}, these amphiphilic antibiotics are attractive targets for new drug discovery.

In these studies, we would like to report the design and synthesis of a new hybrid analogue, cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-Pro-D-Tyr-) (**7a**), containing

both the sequences of the (GS) pentapeptide (-Val-Orn-Leu-D-Phe-Pro-) and the (GR) hexapeptide (-Val-Orn-Leu-D-Phe-Pro-D-Tyr-) in the molecule (Fig. 1). The antiparallel β -sheet conformations of GS and GR place the charged Orn side chains on one side of the plane of the molecule and the hydrophobic Val and Leu side chains on the other side, and this plays an important role for exhibiting high antibiotic activity.²⁾ If each conformation of the partial sequences in the GS and GR molecules held in the hybrid analogue (**7a**), **7a** may possess the side-chain arrangement required for exhibiting the activity of GS and GR, even though **7a** is not C₂ symmetric. Further, we synthesized the two cycloundecapeptides, cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-D-Tyr-Pro-) (**7b**) and cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-Pro-D-Phe-D-Tyr-) (**7c**), which are hybrids of GS and two GR peptides possessing the high antibiotic activity, cyclo(-Val-Orn-Leu-D-Phe-D-Tyr-Pro-)₂ (**GR2**) and cyclo(-Val-Orn-Leu-Pro-D-Phe-D-Tyr-)₂ (**GR3**), respectively (Fig.1).

The synthesis of peptide **7a** was performed by a conventional liquid phase method. (Fig. 2) Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OBzl (**1a**)^{††} and Boc-Val-Orn(Z)-Leu-D-Phe-Pro-OBzl (**2a**) were synthesized from Pro benzyl ester by step-by-step elongation using 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole, and then saponified to give Boc-hexapeptide (**3a**) and Boc-pentapeptide (**4a**). Compound **3a** was converted into the corresponding succinimide ester (**3a'**) with EDCI and *N*-hydroxysuccinimide (HONSu).

Fig. 1. Primary structure of gramicidin S (GS), gratisin peptides (GR, GR2, and GR3) and its hybrid analogous (**7a~7c**).

	1	2	3	4	5	6	7	8	9	10	11	12
GS.	cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-Pro-)											
GR.	cyclo(-Val-Orn-Leu-D-Phe-Pro-D-Tyr-Val-Orn-Leu-D-Phe-Pro-D-Tyr-)											
GR2.	cyclo(-Val-Orn-Leu-D-Phe-D-Tyr-Pro-Val-Orn-Leu-D-Phe-D-Tyr-Pro-)											
GR3.	cyclo(-Val-Orn-Leu-Pro-D-Phe-D-Tyr-Val-Orn-Leu-Pro-D-Phe-D-Tyr-)											
	1	2	3	4	5	6	7	8	9	10	11	
7a.	cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-Pro-D-Tyr-)											
7b.	cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-D-Tyr-Pro-)											
7c.	cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-Pro-D-Phe-D-Tyr-)											

* Corresponding author: tamaki@chem.sci.toho-u.ac.jp

[†] Amino acid residues with no prefix are of L-configuration. The abbreviations of amino acids and peptides are in accordance with the rules of IUPAC-IBU commission of Biological Nomenclature.

^{††} Abbreviations used are as follows: Boc, *t*-butoxycarbonyl; Z, benzyloxycarbonyl; OBzl, Benzyloxy; BzlCl₂, 2,6-dichlorobenzyl.

Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OBzl (**1a**)
 | NaOH
 Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OH (**3a**)
 | HONSu/EDCI
 Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-ONSu (**3a'**)
 |
 Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-OH (**5a**)
 | HONSu/EDCI
 Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-ONSu (**5a'**)
 | TFA
 H-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-ONSu·TFA
 | in pyridine
 cyclo(-Val-Orn(Z)-Leu-D-Phe-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-D-Tyr(BzlCl₂)-) (**6a**)
 | H₂/Pd, HCl in MeOH
 cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-Pro-D-Tyr-)·2HCl (**7a**)

	yield (%)	mp (° C)	$[\alpha]_D^{25}$ (°) (c 0.5, DMF)	Formula(MW) ^{a)}
2c. Boc-D-Phe-D-Tyr(BzlCl ₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OBzl	51	215-216	-13.5	C ₇₅ H ₉₁ O ₁₃ N ₈ Cl ₂ ·0.5H ₂ O (1392.5)
4c. Boc-D-Phe-D-Tyr(BzlCl ₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OH	90	198-200	-12.6	C ₆₈ H ₈₅ O ₁₃ N ₈ Cl ₂ ·0.5H ₂ O (1302.4)
5a. Boc-D-Tyr(BzlCl ₂)-Val-Orn(Z)-Leu-D-Phe-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-OH	55	190-194	-37.3 (c 1)	C ₉₇ H ₁₂₈ O ₂₀ N ₁₃ Cl ₂ ·2.5H ₂ O(1896.1)
5b. Boc-Val-Orn(Z)-Leu-D-Phe-D-Tyr(BzlCl ₂)-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-OH	94	148-149	-37.8 (c 1)	C ₉₇ H ₁₂₈ O ₂₀ N ₁₃ Cl ₂ ·1.5H ₂ O(1878.1)
5c. Boc-Val-Orn(Z)-Leu-Pro-D-Phe-D-Tyr(BzlCl ₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OH	95	162	-16.5	C ₉₇ H ₁₂₈ O ₂₀ N ₁₃ Cl ₂ ·2H ₂ O (1887.1)
6a. cyclo[-D-Tyr(BzlCl ₂)-Val-Orn(Z)-Leu-D-Phe-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-]	35	237-240	-110.3	C ₉₂ H ₁₁₈ O ₁₆ N ₁₃ Cl ₂ ·2.5H ₂ O(1778.0)
6b. cyclo[-Val-Orn(Z)-Leu-D-Phe-D-Tyr(BzlCl ₂)-Pro-Val-Orn(Z)-Leu-D-Phe-Pro-]	45	231-233	-61.2	C ₉₂ H ₁₁₈ O ₁₆ N ₁₃ Cl ₂ ·4H ₂ O (1805.0)
6c. cyclo[-Val-Orn(Z)-Leu-Pro-D-Phe-D-Tyr(BzlCl ₂)-Val-Orn(Z)-Leu-D-Phe-Pro-]	37	220 (decomp.)	-42.5 (c 0.3)	C ₉₂ H ₁₁₈ O ₁₆ N ₁₃ Cl ₂ ·2H ₂ O (1769.0)

b) Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OBzl (**1a**), Boc-D-Tyr(BzlCl₂)-Val-Orn(Z)-Leu-D-Phe-Pro-OH (**3a**), Boc-Val-Orn(Z)-Leu-D-Phe-Pro-OBzl (**2a** and **2b**), Boc-Val-Orn(Z)-Leu-D-Phe-Pro-OH (**4a** and **4b**), Boc-Val-Orn(Z)-Leu-D-Phe-D-Tyr(BzlCl₂)-Pro-OBzl (**1b**), and Boc-Val-Orn(Z)-Leu-D-Phe-D-Tyr(BzlCl₂)-Pro-OH (**3b**), have been reported in the literature.^{7,20)}

Table 2. Yields and analytical data of hybrid analogs **7a**~**7c**.

7a.	cyclo(-Val-Orn-Leu-D-Phe-Pro-D-Tyr-Val-Orn-Leu-D-Phe-Pro-)·2HCl yield, 65% ; mp 248-250 °C (decomp.) ; [α] _D ²⁵ -172.0 ° (c 0.5, EtOH). MS (FAB), m/z 1304 (C ₆₉ H ₁₀₂ O ₁₂ N ₁₃ ; M+H ⁺). Amino acid analysis : Val, 2.20 ; Orn, 2.10 ; Leu, 2.20 ; Phe, 2.10 ; Pro, 1.92 ; Tyr, 1.00 Found: C, 55.49 ; H, 7.58 ; N, 12.30%. Calcd for C ₆₉ H ₁₀₂ O ₁₂ N ₁₃ ·2HCl·6.5H ₂ O: C, 55.41 ; H, 7.88 ; N, 12.17%.
7b.	cyclo(-Val-Orn-Leu-D-Phe-D-Tyr-Pro-Val-Orn-Leu-D-Phe-Pro-)·2HCl yield, 90% ; mp 228-231 °C (decomp.) ; [α] _D ²⁵ -164.2 ° (c 0.5, EtOH). MS (FAB), m/z 1304 (C ₆₉ H ₁₀₂ O ₁₂ N ₁₃ ; M+H ⁺). Amino acid analysis : Val, 1.96 ; Orn, 1.90 ; Leu, 2.08 ; Phe, 2.04 ; Pro, 2.06 ; Tyr, 1.00 Found: C, 55.88 ; H, 7.57 ; N, 12.23%. Calcd for C ₆₉ H ₁₀₂ O ₁₂ N ₁₃ ·2HCl·6H ₂ O: C, 55.75 ; H, 7.86 ; N, 12.25%.
7c.	cyclo(-Val-Orn-Leu-Pro-D-Phe-D-Tyr-Val-Orn-Leu-D-Phe-Pro-)·2HCl yield, 99% ; mp 225 °C (decomp.) ; [α] _D ²⁵ -131.0 ° (c 0.5, EtOH). MS (FAB), m/z 1304 (C ₆₉ H ₁₀₂ O ₁₂ N ₁₃ ; M+H ⁺). Amino acid analysis : Val, 2.10 ; Orn, 2.00 ; Leu, 2.20 ; Phe, 2.10 ; Pro, 1.90 ; Tyr, 1.00 Found: C, 57.72 ; H, 7.87 ; N, 12.63%. Calcd for C ₆₉ H ₁₀₂ O ₁₂ N ₁₃ ·2HCl·3.5H ₂ O: C, 57.45 ; H, 7.82 ; N, 12.62%.

Table 3. Antibiotic activities of **GS** and hybrid peptides **7a**~**7c**.

Test organisms	Minimum inhibitory concentration (μg/ml) ^{a)}			
	GS	7a	7b	7c
<i>S. aureus</i> Smith	3.13	3.13	3.13	6.25
<i>S. aureus</i> MS353 AO	3.13	3.13	3.13	6.25
<i>S. aureus</i> 0175	3.13	6.25	3.13	6.25
<i>S. epidermidis</i> ATCC 27626	3.13	3.13	3.13	6.25
<i>S. pyogenes</i> N.Y.5	3.13	3.13	3.13	3.13
<i>S. pyogenes</i> S-23	3.13	3.13	6.25	3.13
<i>S. agalactiae</i> ATCC 12386	3.13	3.13	3.13	6.25
<i>M. luteus</i> ATCC 9341	3.13	6.25	12.5	6.25
<i>B. subtilis</i> ATCC 6633	3.13	3.13	3.13	3.13
<i>E. coli</i> NIHJ-JC2	>100	>100	>100	>100
<i>K. pneumoniae</i> NCTC 9632	12.5	25	>100	>100
<i>P. aeruginosa</i> PA01	>100	>100	>100	>100

a) Minimum inhibitory concentration (μg/ml) was determined by an agar dilution method with 10⁶ organisms per milliliter.

Coupling of **3a'** with pentapeptide derived from **4a** afforded the undecapeptide (**5a**), which was converted into the undecapeptide succinimide ester (**5a'**). Boc-group of **5a'** was removed by the action of trifluoroacetic acid (TFA), and then the succinimide ester was cyclized under high dilution (peptide concentration: 3×10^{-3} M) in pyridine at 45°C for 3 hours. The resulting product was purified by means of high-performance liquid chromatography, followed by recrystallization. The cycloundecapeptide (**6a**) was obtained in 35% yield. The removal of all the masking groups of **6a** by hydrogenolysis yielded **7a**. Peptides **7b** and **7c** were synthesized in a similar manner, in 45 and 37% cyclization yields, respectively. The homogeneity of hybrid analogs **7a~7c** was confirmed by means of thin-layer chromatography, amino acid analysis, HPLC, elemental analysis, and FAB mass spectrometry (Table 1 and 2).

The antibiotic activity of these hybrid analogues **7a~7c** and GS is summarized in Table 3. The hybrid analogue **7a** showed antibiotic activity against all Gram-positive microorganisms tested, and its activity is the same activity as that of GS. Other hybrid analogues **7b** and **7c** also showed strong activity. These results suggest that a secondary structure having the side-chain arrangement required for the antibiotic activity is present in these hybrid analogues, despite the fact that their primary structure is not C_2 symmetric.

To investigate the structure-activity relationship of these hybrid analogues, CD spectra of GS, GR peptides and the

three hybrid analogues, **7a~7c**, were measured in aqueous solutions (Fig. 3). The shapes of the CD spectra of **7a~7c** are similar to the graphical average of the CD spectra of the GS and GR peptides, but the trough of the CD curves is slightly shallower than their graphical averages. The difference found in the ellipticities of these compounds seems to reflect the difference of the stability of their structures in aqueous solutions. We reported that the CD spectra of the GS and GR peptides reflect the ring features near the Pro residue, but not always the entire structure of the molecule.^{7,19)} The existence of additivity in CD spectra suggests that these hybrid analogs have both conformations around the β -turn part of the GS and GR peptides, in other words, structures with the side-chain arrangement required for exhibiting the activity of GS and GR peptides.

Further detailed conformational analysis of these hybrid peptides are needed in order to clearly understand the structure-activity relationship.

Acknowledgments

I thank to the staff of the Research Laboratories of Asahi Chemical Industry Co. for their elemental analysis, microbiological assays, and the measurement of the FAB mass.

References

- 1) BATTERSBY, A. R. & L. C. CRAIG: The molecular weight

Fig. 3. CD spectra of GS, GR peptides and its hybrid analogs **7a~7c** in aqueous solution.

- determination of polypeptides. J. Am. Chem. Soc. 73: 1887~1888, 1951
- 2) IZUMIYA, N.; T. KATO, H. AOYAGI, M. WAKI & M. KONDO: "Synthetic Aspects of Biologically Active Cyclic Peptide-Gramicidin S and Tyrocidines", Kodansha, Tokyo, and Halsted press, New York, 1979
- 3) ZHARIKOVA, G. G.; S. P. MYASKOVSKAYA & A. B. SILAEV: Antibiotic gratisin derived from the cells of the mutant *Bacillus brevis* strain Y-33. Vestn. Mosk. Univ. Biol. Pochvoved. 27: 110~112, 1972
- 4) MYASKOVSKAYA, S. P.; G. G. ZHARIKOVA & A. B. SILAEV: Amino acid composition and some of the physicochemical properties of gratisin. Vestn. Mosk. Univ. Biol. Pochvoved. 28: 123~125, 1973
- 5) TAMAKI, M.; M. TAKIMOTO, S. SOFUKU & I. MURAMATSU: Synthetic studies on gratisin. J. Antibiotics 34: 1227~1228, 1981
- 6) TAMAKI, M.; M. TAKIMOTO, S. SOFUKU & I. MURAMATSU: Synthetic studies on gratisin II. J. Antibiotics 36: 751~752, 1983
- 7) TAMAKI, M.: Studies on peptide antibiotic "gratisin". Bull. Chem. Soc. Jpn. 57: 3210~3220, 1982
- 8) TAMAKI, M.; M. TAKIMOTO & I. MURAMATSU: Studies of a peptide antibiotic "gratisin" II. Bull. Chem. Soc. Jpn. 60: 2101~2104, 1987
- 9) TAMAKI, M.; M. TAKIMOTO, S. NOZAKI & I. MURAMATSU: Adsorption of cyclic peptides analogous to gramicidin S and gratisin onto octadecylsilica stationary phase and bacteria cells. J. Chromatogr. 413: 287~292, 1987
- 10) HODGKIN, D. C. & B. M. OUGHTON: Possible molecular models for gramicidin S and their relationship to present ideas of protein structure. Biochem. J. 65: 752~756, 1957
- 11) STERN, A.; W. A. GIBBONS & L. C. CRAIG: A conformational analysis of gramicidin S~A by nuclear magnetic resonance. Proc. Natl. Acad. Sci. USA 61: 734~741, 1968
- 12) OHNISHI, M. & D. W. URRY: Temperature dependence of amide proton chemical shifts: The secondary structures of gramicidin S and valinomycin. Biochim. Biophys. Res. Commun. 36: 194~202, 1969
- 13) PRENNER, E. J.; R. N. A. H. LEWIS & R. N. McELHANEY: The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes. Biochem. Biophys. Acta 1462: 201~221, 1999
- 14) HANCOCK, R. E. W.: Peptide antibiotics. The Lancet 349: 418~422, 1997
- 15) TRAVIS, J.: As the development of antibiotic-resistant bacteria accelerated, research on new antibiotics lags. But a few promising lines of investigation remain open. Science 264: 360~362, 1994
- 16) KOHLI, R. M.; C. T. WALSH & M. D. BURKART: Biomimetic synthesis and optimization of cyclic antibiotics. Nature 418: 658~661, 2002
- 17) BU, X.; X. WU, G. XIE & Z. GUO: Synthesis of tyrocidine A and its analogues by spontaneous cyclization in aqueous solution. Org. Lett. 4: 2893~2895, 2002
- 18) WU, X.; X. BU, K. M. WONG, W. YAN & Z. GUO: Biomimetic synthesis of gramicidin S and analogues by enzymatic cyclization of linear precursors on solid support. Org. Lett. 5: 1749~1752, 2003
- 19) TAMAKI, M.; T. OKITSU, M. ARAKI, H. SAKAMOTO, M. TAKIMOTO & I. MURAMATSU: Synthesis and properties of gramicidin S analogs containing D-Phe-PRO-L-D-Val or L-Phe-L-Pro-D-Val sequences in place of D-Phe-L-Pro-L-Val sequence in the β -turn part of the antibiotic. Bull. Chem. Soc. Jpn. 58: 531~535, 1985
- 20) TAMAKI, M.; T. OKITSU, M. ARAKI, H. SAKAMOTO, M. TAKIMOTO & I. MURAMATSU: CD spectra and cyclization of linear pentapeptides as gramicidin S precursors with a benzyloxycarbonyl group on the side chain of ORN residue. Bull. Chem. Soc. Jpn. 66: 3113~3115, 1993